Current Headlines

  1. Genesis Drug Discovery & Development Announces Operating Agreement With Ophthy-DS, Inc.

    PharmOptima, a member of Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) arm of Genesis Biotechnology Group® (GBG), and Ophthy-DS, a preclinical CRO providing ocular drug discovery services, have announced a collaborative operating agreement

  2. Emerald Health Pharmaceuticals’ Cannabinoid-Derived Drug Candidate, EHP-102, Shows Potential Disease-Modifying Activity In Huntington’s Disease Models

    Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that newly published scientific data support the potential of EHP’s oral drug candidate, EHP-102, to be disease-modifying for Huntington’s disease (HD)

  3. Provectus Provides Update On Metastatic Uveal Melanoma Clinical Development Program For Investigational Drug PV-10

    Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational cancer agent PV-10. Intratumoral injection of small molecule oncolytic immunotherapy PV-10 can yield immunogenic cell death in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells1-4, which may lead to a functional recruitment of the immune system

  4. Celgene And Exscientia Enter 3-Year AI Drug Discovery Collaboration Focused On Accelerating Drug Discovery In Oncology And Autoimmunity

    Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced recently that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25M upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program

  5. First Cancer Patient Receives Dose Of Super-Enhancer Inhibitor GZ17-6.02, An Advanced Cancer Drug From Genzada Pharmaceuticals, At HonorHealth Research Institute

    Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced recently that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz

  6. Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

    The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in accordance with FDA guidelines

  7. Tiziana Submits IND Application For Oral Formulation Of Foralumab For Treatment Of NASH

    Tiziana Life Sciences plc (the "Company", "Tiziana Life Sciences" or "Tiziana") (NASDAQ: TLSA; AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers

  8. Novo Nordisk Files For US FDA Approval Of Oral Semaglutide For Blood Sugar Control And Cardiovascular Risk Reduction In Adults With Type 2 Diabetes

    Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill

  9. AlzeCure Initiates New Drug Project Within Pain

    AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that it has started a new preclinical drug project, TrkA-NAM, which is based on the company's research platform NeuroRestore

  10. Cyxone Announces Strategic Intent To Position Its Drug Candidate T20K In MS As A Prophylactic Agent

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K as a prophylactic agent for the treatment of multiple sclerosis (MS). This indicates that the substance could be used to mitigate or prevent MS episodes and potentially even delay the disease progression. Early disease intervention, such as this, is currently not targeted by other treatments available